HEMOGENYX PHARMACEUTICALS ORD GBP0.01 overview

Admission of New Ordinary Shares and New ISIN LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of the New Ordinary Shares (as defined below) further to the passing of all resolutions at its Extraordinary General Meeting (the "Meeting") held on 9 December 2024. At the...

Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1 LONDON, UNITED KINGDOM / ACCESSWIRE / December 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, is pleased to announce the successful completion of the Site Initiation Visit at the first clinical site for its Phase I clinical trial of HG-CT-1 (also known as HEMO-CAR-T). The...

Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical company, is pleased to announce a breakthrough in its development of a novel method for delivering Chimeric Bait Receptors ("CBR") to innate immune cells such as macrophages and monocytes i.e. the white myeloid blood cells that make up the body's first line of defence against...

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Notice of Extraordinary General Meeting Proposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group focused on developing new therapies for blood diseases announces that it has posted, or otherwise made available, a circular to shareholders containing a notice convening an Extraordinary General Meeting...

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB) of the Company's first clinical site has granted approval to initiate a Phase I clinical trial of the Company's lead asset, HEMO-CAR-T , which has now...

Institutional Investment of £600,000 Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical group focused on developing new therapies for blood diseases, is pleased to announce that it was approached by an institutional investor and that this investor has subscribed £600,000, for the issue of 60,000,000 new...

Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening of the first clinical site for its lead asset, HEMO-CAR-T, formally designated HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia...

Prevail Partners, LLC to invest again in Hemogenyx Pharmaceuticals Prevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces tha tPrevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest a total of $350,000...